The C-reactive protein (CRP)-to-lymphocyte ratio (CLR) is an emerging inflammation-based biomarker that has demonstrated prognostic value in various conditions, including malignancies, COVID-19, and acute pancreatitis [2-4]. The gene discussed is CRP; the disease is COVID-19.